Predictive Molecular Markers: Has the Time Come for Routine Use in Lung Cancer?

Authors:
Angela M. Davies
Search for other papers by Angela M. Davies in
Current site
Google Scholar
PubMed
Close
 MD
,
Philip C. Mack
Search for other papers by Philip C. Mack in
Current site
Google Scholar
PubMed
Close
 PhD
,
Primo N. Lara Jr.
Search for other papers by Primo N. Lara Jr. in
Current site
Google Scholar
PubMed
Close
 MD
,
Derick H. Lau
Search for other papers by Derick H. Lau in
Current site
Google Scholar
PubMed
Close
 MD, PhD
,
Kathleen Danenberg From the Division of Hematology/Oncology, Department of Internal Medicine, University of California Davis Cancer Center, Sacramento, California and Response Genetics, Los Angeles, California.

Search for other papers by Kathleen Danenberg in
Current site
Google Scholar
PubMed
Close
 PhD
,
Paul H. Gumerlock
Search for other papers by Paul H. Gumerlock in
Current site
Google Scholar
PubMed
Close
 PhD
, and
David R. Gandara
Search for other papers by David R. Gandara in
Current site
Google Scholar
PubMed
Close
 MD
Full access

Although some evidence exists to support the use of clinical factors such as performance status and weight loss to predict response and toxicity to therapy in non-small cell lung cancer (NSCLC) patients, researchers have shown little prospective data on the use of molecular markers to facilitate selection of specific chemotherapy or new molecularly targeted agents in this patient population. Breast cancer exemplifies the growing role that molecular markers are playing, not only as prognostic factors, but also in predicting response to targeted treatments such as hormonal therapy, and more recently, trastuzumab (Herceptin). Although several studies have examinedmolecular markers in lung cancer and have shown promising potential value, these studies were retrospective and require prospective validation. To identify molecular markers that reliably predict response and to be able to individualize cytotoxic and targeted therapy for NSCLC patients are the ultimate goals of future trials. This article focuses on a selected number of promising markers under study in lung cancer, including those thought to play roles in response to DNA damaging chemotherapy (excision repair cross-complementing [ERCC1], xeroderma pigmentosum group D [XPD]), taxane resistance (-tubulin III), antimetabolite therapy (RRM1), irinotecan metabolism (UGT1A1) and epidermal growth factor receptor (EGFR) pathway inhibition. To date, none of these markers can be recommended for routine use in clinical practice.

Correspondence: Angela M. Davies, MD, University of California at Davis Cancer Center, 4501 X Street, Suite 3016, Sacramento, California 95817. E-mail: angela.davies@ucdmc.ucdavis.edu
  • Collapse
  • Expand
  • 1

    Bunn PA Jr, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 1998;4:10871100.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2

    Marino P, Pampallona S, Preatoni A et al.. Chemotherapy vs supportive care in advanced non-small-cell lung cancer: Results of a meta-analysis of the literature. Chest 1994;106:861865.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3

    Rapp E, Pater JL, Willan A et al.. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer—report of a Canadian multicenter randomized trial. J Clin Oncol 1988;6:633641.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4

    Rosell R, Taron M, Alberola V et al.. Genetic testing for chemotherapy in non-small cell lung cancer. Lung Cancer 2003;41(Suppl 1):S97S102.

  • 5

    Marnellos G. High-throughput SNP analysis for genetic association studies. Curr Opin Drug Discov Devel 2003;6:317321.

  • 6

    Jiang H, Yang LY. Cell cycle checkpoint abrogator UCN-01 inhibits DNA repair: association with attenuation of the interaction of XPA and ERCC1 nucleotide excision repair proteins. Cancer Res 1999;59:45294534.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7

    Taylor EM, Broughton BC, Botta E et al.. Xeroderma pigmentosum and trichothiodystrophy are associated with different mutations in the XPD (ERCC2) repair/transcription gene. Proc Natl Acad Sci USA 1997;94:86588663.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8

    Dabholkar M, Vionnet J & Bostick-Bruton F. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 1994;94:703708.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9

    Metzger R, Leichman CG, Danenberg KD. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998;16:309316.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10

    Lord RV, Brabender J, Gandara D et al.. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002;8:22862291.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11

    Rosell-Costa R, Danenberg K, Alberola V et al.. Taron, ERCC1 and RRM1 expression predicts survival: A genetic analysis of a Spanish Lung Cancer Group trial of gemcitabine (gem)/cisplatin (cis) vs gem/cis/vinorelbine (vrb) vs sequential doublets of gem/vrb and vrb/ifosfamide (ifos) in stage IV non-small-cell lung cancer (NSCLC) (Abstract #2590). Proc Am Soc Clin Onc 2003;22.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12

    Taron M, Alberola V, Sanchez JJ et al.. Transcription-coupled repair (TCR) XPD and RRM1 gene polymorphisms predict gemcitabine (gem)/cisplatin (cis) outcome in non-small-cell lung cancer (NSCLC) (Abstract #2579). Proc Am Soc Clin Onc 2003;22.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13

    Gurubhagavatula S, Liu G, Park S et al.. XPD and XRCC1 genetic polymorphisms are associated with overall survival (OS) in advanced non-small cell lung cancer (NSCLC) patients treated with platinum chemotherapy. (Abstract #491). Proc Am Soc Clin Onc 2003;22.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14

    Cardenal F, Ramirez JL, Astudillo J et al.. XPD and RRM1 gene polymorphisms predict gemcitabine (gem)/cisplatin (cis)/docetaxel (doc) outcome in stage III non-small-cell lung cancer (NSCLC): A genetic analysis of the Spanish Lung Cancer Group phase II trial 9901 (Abstract #2612). Proc Am Soc Clin Onc 2003;22.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15

    Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 1980;77:15611565.

  • 16

    Monzo M, Rosell R, Sanchez JJ et al.. Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol 1999;17:17861793.

  • 17

    Kelley MJ, Li S, Harpole DH. Genetic analysis of the beta-tubulin gene, TUBB, in non-small-cell lung cancer. J Natl Cancer Inst 2001;93:18861888.

  • 18

    Derry WB, Wilson L, Khan IA et al.. Taxol differentially modulates the dynamics of microtubules assembled from un-fractionated and purified beta-tubulin isotypes. Biochemistry 1997;36:35543562.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19

    Kavallaris M, Burkhart CA, Horwitz SB. Antisense oligonucleotides to class III beta-tubulin sensitize drug-resistant cells to Taxol. Br J Cancer 1999;80:10201025.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20

    Mack PC, Galvin IV, Kimura T et al.. Molecular abnormalities of DNA damage and anti-microtubule response pathways in non-small cell lung carcinomas (NSCLC) from patients on the Southwest Oncology Group (SWOG) 9509 trial (Abstract #2569). Proc Am Soc Clin Onc 2003;22:39.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21

    Rosell R, Scagliotti G, Danenberg KD et al.. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 2003;22:35483553.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22

    Bjorklund S, Skog S, Tribukait B, Thelander L. S-phase-specific expression of mammalian ribonucleotide reductase R1 and R2 subunit mRNAs. Biochemistry 1990;29: 54525458.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23

    Rosell R, Crino L, Danenberg K et al.. Targeted therapy in combination with gemcitabine in non-small cell lung cancer. Semin Oncol 2003;30:1925.

  • 24

    Iyer L, King CD, Whitington PF et al.. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998;101:847854.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25

    Ando Y, Saka H, Ando M et al.. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000;60:69216926.

  • 26

    Innocenti F, Undevia SD, Iyer L et al.. UGT1A1*28 polymorphism is a predictor of neutropenia in irinotecan chemotherapy (Abstract #49J, p. 24). Proc Am Soc Clin Onc 2003;124.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27

    Innocenti F, Ratain MJ. Irinotecan treatment in cancer patients with UGT1A1 polymorphisms. Oncology (Huntingt) 2003;17:5255.

  • 28

    Font A, Taron M, Rosell R et al.. UGT1a1 genotyping correlates with toxicity and survival in non-small-cell lung cancer (NSCLC) patients treated with second-line CPT-11/docetaxel (Abstract #1357). Proc Am Soc Clin Onc 2001;20.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29

    Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183232.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30

    Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002;20(Suppl 18):1S13S.

  • 31

    Brabender J, Danenberg KD, Metzger R et al.. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 2001;7:18501855.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32

    Perez-Soler R, Chachoua A, Huberman M et al.. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum based chemotherapy, inpatients with advanced, EGFR-expressing non-small cell lung cancer (Abstract #1235). Proc Am Soc Clin Oncol 2001;20.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33

    West HL, Franklin WA, Gumerlock P et al.. ZD1839 (Iressa) in advanced bronchioalveolar carcinoma (BAC): A preliminary report of SWOG 0126. Abstract O-187. Proc World Conf Lung Cancer 2003;41(Suppl 2):S56.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34

    Moasser MM, Basso A, Averbuch SD, Rosen N. The tyrosine kinase inhibitor ZD1839 (“Iressa”) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 2001;61:71847188.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35

    Cappuzzo F, Gregorc V, Rossi E et al.. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol 2003;21:26582663.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36

    Mitsudomi T, Yatabe Y, Tada H et al.. Lack of predictive value of p53, p27, Bcl2, HER2/neu, EGFR alterations for efficacy of postoperative adjuvant chemotherapy consisting of cisplatin plus vindesine in patients with non-small cell lung cancer (NSCLC) with mediastinal node involvement (JCOG9304A) (Abstract #2653). Proc Am Soc Clin Onc 2003;22:660.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37

    Le Chevalier T, IALT Investigators. Results of the randomized International Adjuvant Lung Cancer Trial (IALT): cisplatin-based chemotherapy (CT) vs no CT in 1867 patients (pts) with resected non-small cell lung cancer (NSCLC) (Abstract). Proc Am Soc Clin Onc 2003;22.

    • PubMed
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 698 415 12
PDF Downloads 152 27 0
EPUB Downloads 0 0 0